Resumo

LOPEZ-HERNANDEZ, MA. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, kidney as objective in the glycemic control of diabetes mellitus type 2. Med. interna Méx. [online]. 2017, vol.33, n.3, pp.363-371. ISSN 0186-4866.

Type 2 diabetes is the most important and prevalent chronic disease today, being an important morbidity and mortality cause worldwide. Despite the great number of medications for diabetes control, many people with this condition do not achieve good glycemic control. Hyperglycemia is the key therapeutic focus in diabetes mellitus management, with many drug families developed to the date for get the target glucose level for prevent the acute and long term complications of this disease. Sodium glucose co-transporter type 2 inhibitors (SGLT2) are a new drug family that reduce renal glucose reabsorption and increase the urinary glucose elimination, thus lowering the blood glucose levels.

Palavras-chave : diabetes therapy; type 2 diabetes mellitus; sodium glucose co-transporter; type 2 inhibitors; glucose homeostasis.